Amneal Pharmaceuticals held a special meeting on July 31, 2026, where stockholders approved the acquisition of 100% of Kashiv BioSciences from its equityholders. The transaction involves issuing 28,942,108 shares of Class A common stock to the sellers and is expected to close in the second half of 2026, pending remaining conditions including regulatory approvals. Amneal Pharmaceuticals operates in the pharmaceutical industry, specializing in generic and specialty drugs.
